Senzime

“Children undergoing surgery deserve nothing but the best possible care and use of technologies that help secure positive perioperative outcomes. We’re proud to now partner with the most prestigious and globally recognized children’s hospital in the US”, stated G.W. Hamilton, US Commercial Vice President of Senzime. “This contract once again validates our position as the market leading solution for quantitative train-of-four monitoring across patients of all ages. Our unique and patient-friendly sensor offerings, our performance metrics and our unmatched clinical support teams distinguish us in these competitive evaluations. The US market for quantitative monitoring is rapidly expanding, and we are excited to be the leader in this field.”
 
Each year, approximately 100 million patients, including children, receive neuromuscular blocking drugs as part of anesthesia to facilitate endotracheal intubation and optimize surgical conditions. These medications paralyze muscles required for breathing, making accurate monitoring during surgery essential for ensuring each patient receives the appropriate dose for a safe and timely recovery.
 
Senzime’s TetraGraph is a state-of-the-art quantitative train-of-four monitoring system used by anesthesiologists at hundreds of leading hospitals worldwide. Its proprietary technology meets the requirements of the recently published US and European clinical guidelines. TetraGraph helps anesthesiologists accurately determine the correct dose of neuromuscular blocking drugs and their antagonists and determines when patients have safely recovered post-surgery.